RegeneRx Biopharmaceuticals, Inc.

3 Bethesda Metro Center, Suite 630
Bethesda
Maryland
20814
United States

Tel: 301-280-1992
Fax: 301-280-1996

Email: info@regenerx.com

Show jobs for this employer

317 articles with RegeneRx Biopharmaceuticals, Inc.

  • RegeneRx Biopharmaceuticals, Inc. is reporting that researchers have demonstrated the therapeutic efficacy of Thymosin Beta 4 as a combination treatment against hyperglycemia -induced changes in human corneal epithelial cells.

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information released by HLB Therapeutics in Korea pursuant to the pre-BLA meeting with the FDA on February 28, 2022.

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration), today announced that Chinese researchers confirmed the ability of Thymosin beta 4 (Tβ4) to protect corneal stromal cells from damage due to ethanol exposure and significantly promote wound healing.

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today published an update regarding the regulatory progress of RGN-259 on the Company's website at www.regenerx.com.

  • RegeneRx Biopharmaceuticals, Inc. today announced that the U.S. FDA has accepted its request for a pre-BLA meeting scheduled for February 28, 2022.

  •  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that its U.S. joint venture, ReGenTree LLC, has submitted a letter to the U.S. FDA requesting a pre-BLA meeting pursuant to RGN-259.

  • RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration), announced that the results of the initial randomized, double-masked, placebo-controlled, phase 3 clinical trial of RGN-259 for the treatment of neurotrophic keratitis will be presented at the 2021 American Ophthalmology Association meeting in New Orleans, LA on November 12-15.

  •  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that a new independent research paper was published identifying Thymosin Beta 4's (Tβ4) potential in the diagnosis and treatment of acute kidney injury and reduction of mortality in patients with sepsis.

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that a new research paper was published demonstrating Thymosin Beta 4's (Tβ4) positive effects on animal models related to Alzheimer's Disease.

  • RegeneRx Biopharmaceuticals, Inc. today announced that GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company

  • RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, has issued a Letter to Stockholders updating its recent financing, the FDA regulatory process for RGN-259, and its 12-month operating strategy.

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has released an update from its U.S. joint venture, ReGenTree LLC, regarding its progress and prospects of a pre-BLA (Biologics License Application) meeting with FDA. 

  • RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration), announced that it closed its previously announced private placement offering of common stock and warrants for gross proceeds of $1,980,000.

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), today announced that it has entered into a definitive agreement with certain institutional and accredited investors, including certain directors and officers of the Company, in connection with a private placement of up to $2,000,000 of shares of its common stock and warrants at a purchase price of $0.20 per share and accompanying warrants

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted a press release from its U.S. joint venture, ReGenTree LLC, on its website pursuant to the completed data analysis of its Phase 3 clinical trial (ARISE-3) with RGN-259 for the treatment of dry eye syndrome,

  •  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the estimated timing of the statistical and regulatory plan for its phase 3 dry eye clinical trial (ARISE-3)

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)  ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops for the treatment of dry eye syndrome

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial database evaluating RGN-259

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, is addressing rumors in the market regarding its ARISE-3 phase 3 dry eye trial. 

  •  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, issued a year-end Letter to Stockholders.  The Letter may be viewed